2019 Could Be the Hottest Year On Record

| May 12, 2019

article image
Climate scientists warn that 2019 may be the warmest year on record largely as the result of a possible El Niño event exacerbated.

Spotlight

PCI Biotech Holding ASA

PCI Biotech is a publicly listed Norwegian biotechnology company with a unique technology to improve localised treatment of cancer. The company has a focused and competent organisation localised at Lysaker just outside Oslo, Norway, with extensive collaboration with international experts and service providers. Clinical development of the lead product started in 2009 and has so far shown very promising results in localised treatment of head & neck cancer. The company has started a Phase II study in head & neck cancer, and is preparing for a phase I/II study in bile duct cancer to start by end of 1H 2013.

OTHER ARTICLES
MEDICAL

Better Purification and Recovery in Bioprocessing

Article | August 2, 2021

In the downstream portion of any bioprocess, one must pick through the dross before one can seize the gold the biotherapeutic that the bioprocess was always meant to generate. Unfortunately, the dross is both voluminous and various. And the biotherapeutic gold, unlike real gold, is corruptible. That is, it can suffer structural damage and activity loss. When discarding the dross and collecting the gold, bioprocessors must be efficient and gentle. They must, to the extent possible, eliminate contaminants and organic debris while ensuring that biotherapeutics avoid aggregation-inducing stresses and retain their integrity during purification and recovery. Anything less compromises purity and reduces yield. To purify and recover biotherapeutics efficiently and gently, bioprocessors must avail themselves of the most appropriate tools and techniques. Here, we talk with several experts about which tools and techniques can help bioprocessors overcome persistent challenges. Some of these experts also touch on new approaches that can help bioprocessors address emerging challenges.

Read More
DIAGNOSTICS

Making Predictions by Digitizing Bioprocessing

Article | April 20, 2021

With advances in data analytics and machine learning, the move from descriptive and diagnostic analytics to predictive and prescriptive analytics and controls—allowing us to better forecast and understand what will happen and thus optimize process outcomes—is not only feasible but inevitable, according to Bonnie Shum, principal engineer, pharma technical innovation, technology & manufacturing sciences and technology at Genentech. “Well-trained artificial intelligence systems can help drive better decision making and how data is analyzed from drug discovery to process development and to manufacturing processes,” she says. Those advances, though, only really matter when they improve the lives of patients. That’s exactly what Shum expects. “The convergence of digital transformation and operational/processing changes will be critical for the facilities of the future and meeting the needs of our patients,” she continues. “Digital solutions may one day provide fully automated bioprocessing, eliminating manual intervention and enabling us to anticipate potential process deviations to prevent process failures, leading to real-time release and thus faster access for patients.” To turn Bioprocessing 4.0 into a production line for precision healthcare, real-time release and quickly manufacturing personalized medicines will be critical. Adding digitization and advanced analytics wherever possible will drive those improvements. In fact, many of these improvements, especially moving from descriptive to predictive bioprocessing, depend on more digitization.

Read More

Spotlight

PCI Biotech Holding ASA

PCI Biotech is a publicly listed Norwegian biotechnology company with a unique technology to improve localised treatment of cancer. The company has a focused and competent organisation localised at Lysaker just outside Oslo, Norway, with extensive collaboration with international experts and service providers. Clinical development of the lead product started in 2009 and has so far shown very promising results in localised treatment of head & neck cancer. The company has started a Phase II study in head & neck cancer, and is preparing for a phase I/II study in bile duct cancer to start by end of 1H 2013.

Events